Murabito M, Salat A, Mueller M R
Dipartimento di Chirurgia Cardiotoracica, Università degli Studi, Vienna.
Minerva Chir. 2000 Mar;55(3):121-7.
Surgical treatment of pulmonary resection for metastatic disease has been proven a valuable therapeutic concept for a variety of neoplasms. Concerning breast cancer, at least 25% of patients develop distant metastases. In spite of increasingly sophisticated palliative therapies, the survival of these patients did not appear significantly prolonged during the last 25 years (19-32 months following diagnosis) and about 95% die from metastatic disease.
Between 1977 and 1997, three epidemiological comparable groups out of a total of 125 patients of our clinic were treated for isolated pulmonary metastasis following breast cancer. Complete data from 96 patients were retrospectively analyzed following stratification to three groups according their surgical therapy: C, complete resection, 28 patients; I, incomplete resection, 34 patients; N, no resection, 34 patients.
Comparison of the three therapy methods concerning stage, histology and receptor levels of the primary tumor, number of metastases and the disease free interval (DFI), as well as adjuvant therapy modalities yielded no significant differences. Mean survival of group C was with 79 months (5-years-survival 80%, 10-years-survival 60%) significantly better compared to groups I and N (p < 0.00002). Mean survival of group I and N was not significantly different (15.5 and 9 months respectively). The DFI had no impact on the survival of group C, but showed a high correlation with the survival of group N (R2 = 0.81).
Routine chest X-ray is necessary in the follow-up of breast cancer patients and if coin lesions occur, thoracic surgeon should be contacted.
手术切除肺部转移性疾病已被证明是治疗多种肿瘤的一种有价值的治疗理念。对于乳腺癌,至少25%的患者会发生远处转移。尽管姑息治疗越来越复杂,但在过去25年中(诊断后19 - 32个月),这些患者的生存期并未显著延长,约95%的患者死于转移性疾病。
1977年至1997年期间,我们诊所共有125例乳腺癌患者,其中三组在流行病学上具有可比性,接受了孤立性肺转移的治疗。对96例患者的完整数据进行回顾性分析,根据手术治疗情况将其分为三组:C组,完全切除,28例;I组,不完全切除,34例;N组,未切除,34例。
比较三种治疗方法在原发肿瘤的分期、组织学和受体水平、转移灶数量和无病生存期(DFI)以及辅助治疗方式方面,未发现显著差异。C组的平均生存期为79个月(5年生存率80%,10年生存率60%),明显优于I组和N组(p < 0.00002)。I组和N组的平均生存期无显著差异(分别为15.5个月和9个月)。DFI对C组的生存期没有影响,但与N组的生存期高度相关(R2 = 0.81)。
乳腺癌患者随访时常规胸部X线检查是必要的,如果发现肺部有可疑病变,应联系胸外科医生。